Related Experiment Video
Updated: Apr 10, 2026
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy
Federica Pagano1, Cinzia Girone1, Francesco Borrelli1
1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Abstract:
Resistance to anti-EGFR therapy remains a major challenge in head and neck squamous cell carcinoma (HNSCC), as adaptive mechanisms driven by drug-tolerant persister cells (DTPs) ultimately compromise treatment efficacy. Here, we identify Interleukin-1 (IL-1)-mediated inflammation as a critical driver of resistance to the anti-EGFR monoclonal antibody cetuximab (CTX). Through meta-analysis of HNSCC patient datasets stratified by lymph node status, together with in vitro studies using sensitive and CTX-resistant HNSCC cell lines and in vivo nude mouse models, we demonstrate that IL-1 in the tumor microenvironment reduces EGFR degradation, thereby promoting receptor stability and therapeutic escape. In sensitive cells, CTX suppresses the IL-1 pathway via direct transcriptional downregulation of IL-1α and IL-1β; however, this regulatory effect is lost in resistant cells, where a sustained IL-1-driven pro-inflammatory program enhances invadopodia formation, proliferation, and metastatic potential. Importantly, pharmacological inhibition of IL-1 in mice restored sensitivity to anti-EGFR therapy and prevented lung metastatic dissemination of resistant cells. These findings uncover an inflammatory axis underlying resistance and suggest that targeting IL-1 may improve EGFR-targeted therapies and limit metastatic spread in HNSCC.
Insights
Interleukin-1 (IL-1) inflammation drives resistance to anti-EGFR therapy in head and neck cancer. Targeting IL-1 restores cetuximab sensitivity and prevents metastasis in preclinical models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy is a significant hurdle in treating head and neck squamous cell carcinoma (HNSCC).
- Drug-tolerant persister cells (DTPs) contribute to adaptive resistance, compromising treatment outcomes.
Purpose of the Study:
- To investigate the role of Interleukin-1 (IL-1)-mediated inflammation in driving resistance to cetuximab (CTX), an anti-EGFR monoclonal antibody, in HNSCC.
- To explore the potential of targeting the IL-1 pathway to overcome resistance and prevent metastasis in HNSCC.
Main Methods:
- Meta-analysis of HNSCC patient datasets stratified by lymph node status.
- In vitro studies using sensitive and CTX-resistant HNSCC cell lines.
- In vivo experiments using nude mouse models.
Main Results:
- IL-1 in the tumor microenvironment reduces EGFR degradation, promoting receptor stability and therapeutic escape in HNSCC.
- CTX suppresses the IL-1 pathway in sensitive cells, but this effect is lost in resistant cells.
- Sustained IL-1 signaling in resistant cells enhances invadopodia formation, proliferation, and metastatic potential.
- Pharmacological IL-1 inhibition in mice restored anti-EGFR sensitivity and prevented lung metastasis.
Conclusions:
- IL-1-mediated inflammation is a critical driver of cetuximab resistance in HNSCC.
- Targeting IL-1 represents a promising therapeutic strategy to enhance EGFR-targeted therapies and reduce metastatic spread in HNSCC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:39The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:17The Tumor Microenvironment
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...